695 related articles for article (PubMed ID: 37828565)
1. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts.
Zeng T; Lu Y; Zhao Y; Guo Z; Sun S; Teng Z; Tian M; Wang J; Li S; Fan X; Wang W; Cai Y; Liao G; Liang X; He D; Wang K; Zhao S
Respir Res; 2023 Oct; 24(1):246. PubMed ID: 37828565
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
[TBL] [Abstract][Full Text] [Related]
3. Transmission Characteristics and Inactivated Vaccine Effectiveness Against Transmission of SARS-CoV-2 Omicron BA.5 Variants in Urumqi, China.
Wang K; Guo Z; Zeng T; Sun S; Lu Y; Wang J; Li S; Luan Z; Li H; Zhang J; Wang Y; Lu Y; Zhao S
JAMA Netw Open; 2023 Mar; 6(3):e235755. PubMed ID: 36995713
[TBL] [Abstract][Full Text] [Related]
4. Distinguishing the Vaccine Effectiveness of Inactivated BBIBP-CorV Vaccine Booster Against the Susceptibility, Infectiousness, and Transmission of Omicron Stains: A Retrospective Cohort Study in Urumqi, China.
Zeng T; Wang K; Guo Z; Sun S; Zhai Z; Lu Y; Teng Z; He D; Wang K; Tian M; Zhao S
Infect Dis Ther; 2023 Oct; 12(10):2405-2416. PubMed ID: 37768483
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study.
He X; Zeng B; Wang Y; Pang Y; Zhang M; Hu T; Liang Y; Kang M; Tang S
Front Immunol; 2023; 14():1257360. PubMed ID: 37915583
[TBL] [Abstract][Full Text] [Related]
6. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness of booster vaccination of inactivated COVID-19 vaccines against susceptibility, infectiousness, and transmission of omicron BA.2 variant: a retrospective cohort study in Shenzhen, China.
Liao Y; Su J; Zhao J; Qin Z; Zhang Z; Gao W; Wan J; Liao Y; Zou X; He X
Front Immunol; 2024; 15():1359380. PubMed ID: 38881892
[TBL] [Abstract][Full Text] [Related]
8. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
Wu JD; Li JX; Liu J; Wang HM; Zhou GH; Li J; Wu D; Chen X; Feng Y; Qi XY; Wang X; Gou JB; Ma TL; Yang XY; Xu LF; Wan P; Zhu T; Wang ZF; Zhu FC;
Lancet Infect Dis; 2023 Sep; 23(9):1020-1030. PubMed ID: 37216958
[TBL] [Abstract][Full Text] [Related]
9. Inactivated SARS-CoV-2 Vaccine Booster Against Omicron Infection Among Quarantined Close Contacts.
Liu D; Feng S; Sha F; Liao Y; Xie X; Huang F; Kong D; Zhang Z; Chen Z; Chen N; Gao W; Feng T; Zhao Z; Li B; Li Y; Zhu F; Yang Z; Lv Q; Feng Z; Tang J
JAMA Netw Open; 2023 Oct; 6(10):e2339507. PubMed ID: 37878315
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case-control study.
Zhang X; Wang Y; Hu C; Xu P; Ma L; Liu L; Sun J; Liu Y; Yang H; Pan F; Hu J; Cao C; Cheng K; Gao D; Lyu Y; Qin W
Hum Vaccin Immunother; 2023 Dec; 19(1):2194189. PubMed ID: 36998173
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis.
Xu S; Li J; Wang H; Wang F; Yin Z; Wang Z
BMC Med; 2023 Apr; 21(1):160. PubMed ID: 37106390
[TBL] [Abstract][Full Text] [Related]
12. Transmission risks of Omicron BA.5 following inactivated COVID-19 vaccines among children and adolescents in China.
Guo Z; Zeng T; Lu Y; Sun S; Liang X; Ran J; Wu Y; Chong MKC; Wang K; Zhao S
Commun Med (Lond); 2024 May; 4(1):92. PubMed ID: 38762678
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of BNT162b2 and Sinovac vaccines against the transmission of SARS-CoV-2 during Omicron-predominance in Hong Kong: A retrospective cohort study of COVID-19 cases.
Zhao S; Guo Z; Sun S; Hung CT; Leung EYM; Wei Y; Wang H; Li K; Yam CHK; Chow TY; Gao J; Jia KM; Chong KC; Yeoh EK
J Clin Virol; 2023 Sep; 166():105547. PubMed ID: 37453162
[TBL] [Abstract][Full Text] [Related]
14. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
[TBL] [Abstract][Full Text] [Related]
15. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
Tamandjou Tchuem CR; Auvigne V; Vaux S; Montagnat C; Paireau J; Monnier Besnard S; Gabet A; Benhajkassen N; Le Strat Y; Parent Du Chatelet I; Levy-Bruhl D
Vaccine; 2023 Mar; 41(13):2280-2288. PubMed ID: 36870880
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China.
Yin Z; Fang Q; Wen T; Zheng C; Fu C; Wang S; Li J; Gong X
Hum Vaccin Immunother; 2023 Dec; 19(1):2163813. PubMed ID: 36704960
[TBL] [Abstract][Full Text] [Related]
17. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB
Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540
[TBL] [Abstract][Full Text] [Related]
18. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco.
Zhang Y; Belayachi J; Yang Y; Fu Q; Rodewald L; Li H; Yan B; Wang Y; Shen Y; Yang Q; Mu W; Tang R; Su C; Xu T; Obtel M; Mhayi A; Razine R; Abouqal R; Zhang Y; Yang X
BMC Public Health; 2022 Aug; 22(1):1584. PubMed ID: 35987605
[TBL] [Abstract][Full Text] [Related]
19. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study.
Huang C; Wei Y; Yan VKC; Ye X; Kang W; Yiu HHE; Shami JJP; Cowling BJ; Tse ML; Castle DJ; Chui CSL; Lai FTT; Li X; Wan EYF; Wong CKH; Hayes JF; Chang WC; Chung AKK; Lau CS; Wong ICK; Chan EW
Lancet Psychiatry; 2023 Jun; 10(6):403-413. PubMed ID: 37141907
[TBL] [Abstract][Full Text] [Related]
20. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
